While the National Vaccine Injury Compensation Program (VICP) does not yet cover COVID-19 vaccines, the National Academy of Sciences, Engineering, and Medicine (NASEM) is currently reviewing the issue of COVID-19 vaccine adverse events and their potential inclusion in the VICP. These include:
- Guillain-Barrè Syndrome (GBS)
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Transverse myelitis (TM)
- Bell’s palsy
- Hearing loss
- Chronic headaches
- Infertility
- Sudden death
- Myocarditis/pericarditis
- Thrombosis with thrombocytopenia syndrome (TTS)
- Immune thrombocytopenic purpura (ITP)
- Thromboembolic events (e.g., cerebrovascular accident (CVA), myocardial infarction
- (MI), pulmonary embolism, deep vein thrombosis (DVT))
- Capillary leak syndrome
This review is expected to provide valuable information on the safety and effectiveness of COVID-19 vaccines and could inform future decisions about whether to add them to the VICP. A report on the NASEM review is expected to be released later this year.
In the meantime, Anapol Weiss is closely monitoring the situation and is prepared to investigate potential injury claims involving the COVID-19 vaccine when it is added to the VICP.
